Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Laughing Water Capital. This analysis is provided for institutional research purposes only and is not investment advice.
"Small-cap value manager substantially increased position in distressed CDMO Lifecore Biomedical after 66% decline from loan covenant default. Views this as balance sheet problem, not business problem, with secular biologics tailwinds intact."
Laughing Water Capital returned 7.5% in Q1 2023, matching the S&P 500 while significantly outperforming the Russell 2000's 2.7% return. The manager focuses on finding cheap stocks in hidden corners of the small-cap market, noting that small-cap valuations relative to large caps are at levels not seen since the March 2020 COVID crisis. The letter centers on a detailed analysis of Lifecore Biomedical, a pure-play CDMO specializing in fill-finish work for biologics that suffered a 66% single-day decline due to technical default on loan covenants. Despite this balance sheet problem, the manager substantially increased the position, viewing it as a distressed opportunity with asymmetric risk-reward. The investment thesis relies on secular tailwinds in the biologics market, where 55% of drugs in development are biologics versus only 43% of current sales, driving demand for specialized manufacturing. The manager expects a strategic sale process to unlock significant value, potentially 5x current levels, supported by recent CDMO transactions at premium multiples and Morgan Stanley's advisory role.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
Very high conviction demonstrated through substantial position increase in Lifecore after detailed fundamental analysis, willingness to invest family wealth alongside clients, and concentrated portfolio approach. Manager provides specific valuation scenarios, replacement cost analysis, and multiple catalyst pathways, showing deep conviction in the investment thesis despite acknowledging initial analytical mistakes.
Growth Outlook
Manager expresses constructive optimism about small-cap opportunities, noting that scary headlines should be ignored when there are many very cheap stocks available. Emphasizes that small-cap to large-cap ratios are at historically attractive levels not seen since March 2020 and February 2001, suggesting a positive opportunity set.
Risk Appetite
Manager demonstrates high risk appetite by substantially increasing position size in a distressed name (Lifecore) after a 66% single-day decline and technical default. States that almost the entirety of his and his family's wealth is invested in the fund, showing strong conviction and willingness to take concentrated risk.
Capital Deployment
Manager substantially increased position size in Lifecore Biomedical, demonstrating active capital deployment into a distressed opportunity. The detailed analysis and willingness to add to a position after a 66% decline shows aggressive deployment behavior, though specific cash level changes are not disclosed.
Forward Guidance
Manager expresses excitement about taking advantage of current investment opportunities regardless of macro headlines. The substantial increase in Lifecore position and detailed analysis of multiple positive scenarios demonstrates clear intent to deploy capital aggressively into attractive situations.
Language Signal
Language is predominantly positive with terms like 'excited', 'homerun', 'attractive', 'opportunity', and 'highly skewed' upside. While acknowledging risks and mistakes, the overall tone emphasizes opportunities and value creation potential rather than defensive concerns.
Perceived Risk
Manager acknowledges balance sheet risks and potential bankruptcy scenarios for Lifecore but frames these as manageable and temporary. Risk discussion is present but not central to the letter, with emphasis on risk-reward asymmetry rather than systemic concerns. Scary headlines are explicitly dismissed as noise.
Opportunity Density
Manager sees abundant opportunities in hidden corners of the small-cap market, describing many very cheap stocks as available. Historical valuation comparisons suggest a rich opportunity set, and the detailed Lifecore analysis demonstrates the manager's ability to find and analyze specific attractive situations.
Time Horizon
Manager demonstrates multi-year investment horizon through 5+ year ownership of Avid Bioservices and willingness to hold through volatility. However, the Lifecore situation involves near-term catalysts including forbearance negotiations and strategic review process expected within 3-6 months, suggesting a medium-term rather than permanent capital approach.
